These findings point to the utility of these surface proteins not only for early response prediction in HR+ breast cancer but also as promising targets for ADCs, particularly SLITRK6, which is currently under clinical evaluation in ADC-based therapies41. Here, SLITRK6 is linked to breast carcinoma.